Boundless Bio Inc. ( ($BOLD) ) has released its Q4 earnings. Here is a breakdown of the information Boundless Bio Inc. presented to its investors.

POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second ...

With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027. “We made important strides in 2024 as we ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Now if we used a monoclonal antibody ie a pd-1 inhibitor that kills the cell with no dna damage that may be viable approach in combination with a chk1 inhibitor. Many variations on this as combo ...

ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early ...

State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International ...

Calcineurin inhibitors are topical and systemic immunosuppressants. They can help treat atopic dermatitis and autoimmune disorders such as lupus and psoriasis. They may also help prevent organ ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.